Skip to main content

Servier, Prognomix Agree to ID Targets for Diabetes, Metabolic Disease Treatments

NEW YORK (GenomeWeb News) – Les Laboratoires Servier and Prognomix today announced a deal to identify novel targets for the development of type 2 diabetes and metabolic disease treatments.

The research and development deal will use Prognomix's platform that is based on genomics and bioinformatics technologies, a database of phenotypic and genotypic data, and results from the analysis of the data. The data analysis serves as the foundation of a knowledgebase that will be used by Servier and Prognomix.

The knowledgebase results from what the partners said is the largest clinical study ever conducted on type 2 diabetes called Advance, for which Servier was the main sponsor.

As part of the deal, Servier will make a "contract signature fee payment" of an undisclosed amount. In return, the French pharma can obtain the rights to use targets resulting from the partnership.

Prognomix is a privately held personalized medicine firm based in Montreal, focused on discovering genetic signatures that may be predictive of disease and developing them for clinical use.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.